What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma
Hematologic Oncology Update
00:00
New Trials and Phase 1/2 Data in the Management of Relapsed/Refractory Mantle Cell Lymphoma
This chapter explores two trials comparing BR to Zanu retuximab in the management of mantle cell lymphoma, discussing response rates, toxicity, and selectivity of the drugs.
Transcript
Play full episode
